Insulinoma

Insulinoma is a functional, usually malignant, neuroendocrine tumor of the pancreatic beta cells that autonomously secretes insulin, leading to hyperinsulinemia and subsequent hypoglycemia. In veterinary medicine, insulinomas are most commonly diagnosed in middle-aged to older dogs, with a strong breed predisposition for large-breed dogs such as German Shepherds, Golden Retrievers, Labrador Retrievers, and Boxers. They are rare in cats. The tumor is typically solitary but can be multifocal, and metastasis to regional lymph nodes, liver, and other abdominal organs is common at the time of diagnosis. The clinical syndrome is dominated by neuroglycopenia, which manifests as weakness, collapse, seizures, and altered mentation, particularly after fasting or exercise. The disease is progressive, and while surgical resection is the primary treatment, medical management with dietary modification and drugs such as diazoxide or prednisone is often necessary to control clinical signs, especially in cases with metastatic disease. The prognosis is guarded to poor, with median survival times ranging from several months to over a year depending on the stage and treatment modality.

The exact etiology of insulinoma in dogs and cats is unknown, but it is believed to arise from spontaneous neoplastic transformation of pancreatic beta cells. No specific viral, bacterial, or environmental causes have been identified. Genetic predisposition is suspected based on breed prevalence, particularly in German Shepherds, Golden Retrievers, Labrador Retrievers, and Boxers, suggesting a heritable component. Chronic hyperinsulinemia or beta-cell hyperplasia may precede tumor formation in some cases, but this is not well-documented. In humans, multiple endocrine neoplasia type 1 (MEN1) syndrome is associated with insulinomas, but a similar syndrome has not been clearly established in veterinary patients. No dietary or toxicological triggers have been identified. The tumor is typically well-differentiated, retaining the ability to synthesize and secrete insulin, but it loses normal regulatory control by glucose levels, leading to inappropriate insulin release even during hypoglycemia.

Insulinoma is the most common endocrine tumor of the pancreas in dogs, accounting for approximately 1-2% of all canine tumors. It is rare in cats. The disease typically affects middle-aged to older dogs, with a median age of 9-10 years (range 3-15 years). There is no strong sex predilection, though some studies suggest a slight male predominance. Breed predispositions include German Shepherds, Golden Retrievers, Labrador Retrievers, Boxers, Standard Poodles, and Irish Setters. Large-breed dogs are overrepresented. The incidence is higher in dogs with a history of obesity or diabetes mellitus, but this is not well-established. No geographic or seasonal variation has been reported. In cats, insulinoma is extremely rare, with only a few case reports; affected cats are typically older (median age 12 years) and may present with similar clinical signs.

Insulinoma arises from pancreatic beta cells that have undergone neoplastic transformation. These cells retain the ability to synthesize and secrete insulin, but they lose the normal glucose-sensing mechanism that regulates insulin release. As a result, insulin is secreted autonomously, leading to hyperinsulinemia. Hyperinsulinemia causes increased glucose uptake by insulin-sensitive tissues (muscle, adipose tissue, liver) and suppresses hepatic gluconeogenesis and glycogenolysis, resulting in hypoglycemia. The brain is highly dependent on glucose for energy, and when blood glucose levels fall below approximately 60 mg/dL (3.3 mmol/L), neuroglycopenia occurs, leading to clinical signs such as weakness, ataxia, confusion, seizures, and coma. Chronic hypoglycemia can also cause counter-regulatory hormone responses (glucagon, epinephrine, cortisol, growth hormone) that may partially compensate but are often insufficient. The tumor is often malignant, with metastasis to regional lymph nodes, liver, and occasionally other organs. The metastatic lesions also secrete insulin, contributing to persistent hyperinsulinemia even after surgical removal of the primary tumor. The severity of clinical signs correlates with the degree of hypoglycemia and the rapidity of glucose decline.

The primary predisposing factor for insulinoma is breed, with certain large-breed dogs such as German Shepherds, Golden Retrievers, Labrador Retrievers, and Boxers being at increased risk. Age is also a factor, as the disease is most common in middle-aged to older dogs (median 9-10 years). There is no clear sex predilection. Obesity may be a risk factor, as it is associated with insulin resistance and hyperinsulinemia, which could promote beta-cell proliferation. Concurrent endocrine disorders such as hypothyroidism or hyperadrenocorticism may also be risk factors, though the association is not strong. No specific dietary or environmental factors have been identified. In cats, the disease is so rare that specific risk factors are not well-defined, but older age appears to be a factor.

Clinical signs of insulinoma are primarily due to neuroglycopenia and the associated sympathetic response. They are often episodic and may be precipitated by fasting, exercise, or excitement. Common signs include weakness, lethargy, ataxia, tremors, disorientation, and collapse. Seizures (generalized or focal) are reported in up to 50% of dogs. Other signs may include polyphagia, weight gain, and behavioral changes such as aggression or anxiety. In severe cases, coma and death can occur. Physical examination is often unremarkable between episodes, but during a hypoglycemic episode, dogs may be obtunded, have a depressed mentation, or show neurological deficits. Cats with insulinoma may present with similar signs, including weakness, seizures, and lethargy. The clinical signs are typically intermittent, and owners may report that the dog 'faints' or has 'spells' that resolve after eating. Chronic hypoglycemia can lead to peripheral neuropathy, manifesting as weakness and muscle atrophy, particularly in the hindlimbs.

Differential diagnoses for insulinoma include other causes of hypoglycemia in dogs and cats. These include: 1) Sepsis or systemic inflammatory response syndrome, which can cause hypoglycemia due to increased glucose utilization and decreased gluconeogenesis. 2) Hepatic insufficiency (e.g., portosystemic shunt, cirrhosis, acute liver failure) leading to decreased glycogen stores and impaired gluconeogenesis. 3) Hypoadrenocorticism (Addison's disease), which can cause hypoglycemia due to cortisol deficiency. 4) Sepsis or severe malnutrition. 5) Insulin overdose or exogenous insulin administration (especially in diabetic animals). 6) Paraneoplastic hypoglycemia associated with non-islet cell tumors (e.g., hepatocellular carcinoma, leiomyoma, or other mesenchymal tumors) that secrete insulin-like growth factor II (IGF-II). 7) Xylitol toxicity in dogs, which causes rapid insulin release and hypoglycemia. 8) Starvation or severe cachexia. 9) Neonatal hypoglycemia in puppies. 10) Glycogen storage diseases (rare). To differentiate, a thorough history, physical examination, and diagnostic testing including blood glucose measurement, insulin levels, and imaging are essential. Key features that support insulinoma include: clinical signs of hypoglycemia, documented low blood glucose (<60 mg/dL) with concurrent high serum insulin levels (>20 µIU/mL), and resolution of signs with glucose administration. Imaging may reveal a pancreatic mass or metastasis.

The diagnostic approach to suspected insulinoma involves a stepwise algorithm: 1) Confirm hypoglycemia: Measure blood glucose after a 12-hour fast (or sooner if signs occur). A blood glucose <60 mg/dL (3.3 mmol/L) is consistent with hypoglycemia. 2) Measure serum insulin levels concurrently with blood glucose. An insulin-to-glucose ratio (insulin [µIU/mL] / glucose [mg/dL]) >0.3 is suggestive of insulinoma, but the most reliable criterion is an absolute insulin level >20 µIU/mL when blood glucose is <60 mg/dL. 3) Rule out other causes of hypoglycemia: Perform a complete blood count, serum biochemistry, urinalysis, and abdominal ultrasound to assess liver function and rule out portosystemic shunt or other tumors. 4) If insulinoma is suspected, perform abdominal ultrasound to identify a pancreatic mass and assess for metastasis. Ultrasound is highly specific but not very sensitive for detecting small insulinomas. 5) If ultrasound is inconclusive, consider advanced imaging such as computed tomography (CT) or magnetic resonance imaging (MRI) of the abdomen, which may better visualize the pancreas and metastatic lesions. 6) Definitive diagnosis is made by histopathology after surgical biopsy or resection. 7) In cases where surgery is not feasible, a presumptive diagnosis can be made based on clinical signs, hypoglycemia, hyperinsulinemia, and imaging findings. 8) Additional tests such as fructosamine (to rule out insulin overdose) or IGF-II levels (for paraneoplastic hypoglycemia) may be considered in atypical cases.

The hallmark laboratory finding is hypoglycemia, with blood glucose typically <60 mg/dL (3.3 mmol/L). Serum insulin levels are inappropriately high (>20 µIU/mL) in the face of hypoglycemia. The amended insulin-to-glucose ratio (AIGR) is calculated as: (serum insulin [µIU/mL] × 100) / (blood glucose [mg/dL] - 30). An AIGR >30 is considered diagnostic for insulinoma. Other laboratory findings may include: 1) Hematology: Usually within normal limits, but stress leukogram may be present. 2) Serum biochemistry: May show mild elevations in liver enzymes (ALT, ALP) if hepatic metastasis is present. Electrolyte disturbances are uncommon. 3) Urinalysis: Typically unremarkable; glucosuria is absent because of hypoglycemia. 4) Blood gas analysis: May reveal metabolic acidosis if severe hypoglycemia has caused lactic acidosis. 5) Biomarkers: Serum fructosamine may be low if there is chronic hypoglycemia, but this is not specific. 6) Endocrine assays: Serum insulin levels are the most important. In some cases, C-peptide levels (if available) can be measured to confirm endogenous insulin secretion. 7) Other tests: Liver function tests (bile acids, ammonia) may be performed to rule out hepatic insufficiency. 8) In cats, similar findings are expected, but insulinoma is rare.

Imaging plays a crucial role in the diagnosis and staging of insulinoma. Abdominal ultrasonography is the most commonly used modality. It may reveal a solitary, well-defined, hypoechoic nodule within the pancreas, but sensitivity is low (approximately 30-50%) for detecting small tumors. Ultrasonography is also useful for detecting metastasis to regional lymph nodes (enlarged, hypoechoic) and the liver (target lesions or hypoechoic nodules). Doppler ultrasound may show increased vascularity in the tumor. Computed tomography (CT) of the abdomen is more sensitive than ultrasound for detecting pancreatic masses and metastasis, with reported sensitivity of up to 80%. CT findings include a contrast-enhancing mass in the pancreas, often with heterogeneous enhancement. CT is also superior for surgical planning. Magnetic resonance imaging (MRI) is less commonly used but can provide detailed soft tissue contrast and may be helpful in cases where CT is inconclusive. Endoscopic ultrasound is not widely available in veterinary medicine but has been used experimentally. Thoracic radiographs are recommended to rule out pulmonary metastasis, though this is rare. In all cases, imaging should be performed before surgery to stage the disease and guide surgical resection.

Cytology: Fine-needle aspiration (FNA) of a pancreatic mass or metastatic lesion can be performed under ultrasound guidance. Cytological findings may show clusters of small, round cells with scant cytoplasm and round nuclei, consistent with neuroendocrine cells. However, cytology is often nondiagnostic because the cells are fragile and may not exfoliate well. Immunocytochemistry for insulin or chromogranin A can be performed on cell blocks to confirm the neuroendocrine origin. Histopathology: Definitive diagnosis requires biopsy. Histologically, insulinomas are composed of nests, cords, or trabeculae of well-differentiated beta cells with round nuclei and eosinophilic cytoplasm. The tumor may show capsular invasion, vascular invasion, and mitotic activity. Malignancy is determined by the presence of metastasis, as histologic features alone are not reliable predictors. Immunohistochemistry for insulin, chromogranin A, and synaptophysin is positive. Ki-67 proliferation index may be used to assess aggressiveness. In metastatic lesions, similar histologic features are seen. Surgical biopsy is the gold standard for diagnosis and staging.

Treatment of insulinoma involves a multimodal approach. The primary treatment is surgical resection of the pancreatic mass and any visible metastasis. Surgery is indicated if there is no evidence of extensive metastasis, and the tumor is resectable. Partial pancreatectomy is the most common procedure. During surgery, careful exploration of the abdomen is performed to identify and remove metastatic lesions in the liver and lymph nodes. Postoperative complications include pancreatitis, which can be life-threatening. Medical management is used to control clinical signs in the perioperative period, in cases where surgery is not possible, or as adjunctive therapy. Medical options include: 1) Dietary management: Frequent small meals of a high-protein, low-carbohydrate diet to minimize postprandial insulin spikes. 2) Glucocorticoids (e.g., prednisone) at a starting dose of 0.25-0.5 mg/kg PO q12h, titrated to effect, to increase blood glucose by promoting gluconeogenesis and decreasing peripheral glucose uptake. 3) Diazoxide (Proglycem) at a dose of 10-40 mg/kg/day PO divided q8-12h, which inhibits insulin secretion and is often effective. 4) Somatostatin analogues (e.g., octreotide) at 10-20 µg/kg SC q8-12h, which may reduce insulin secretion in some cases, but efficacy is variable. 5) Chemotherapy with streptozotocin (500 mg/m² IV every 3 weeks) has been used in dogs with metastatic disease, but it is nephrotoxic and requires careful monitoring. 6) In cases of refractory hypoglycemia, continuous glucose infusion may be necessary. 7) Supportive care includes intravenous dextrose for acute hypoglycemic crises. The choice of treatment depends on the stage of disease and the owner's goals. Surgery offers the best chance for long-term survival, but medical management can provide good quality of life for a period.

The prognosis for insulinoma is guarded to poor. Median survival time for dogs treated with surgery alone is approximately 12-18 months, but this varies widely. Dogs with no metastasis at the time of surgery have a median survival of 18 months, while those with metastasis have a median survival of 6-9 months. Medical management alone is associated with a median survival of 6-12 months. Negative prognostic factors include: presence of metastasis at diagnosis, high serum insulin levels, large tumor size, and high Ki-67 index. Dogs that experience severe hypoglycemic episodes have a worse prognosis. Cats with insulinoma have a very poor prognosis, with most surviving less than 6 months. Recurrence is common, even after successful surgery, due to the high malignancy rate. Regular monitoring and adjustment of medical therapy are essential to maintain quality of life.

Follow-up care for insulinoma patients is critical. After surgery, blood glucose should be monitored closely for the first 24-48 hours to detect hyperglycemia (due to pancreatitis or removal of the tumor) or persistent hypoglycemia (due to residual tumor). Serum glucose should be checked every 2-4 hours initially, then gradually less frequently. If the dog remains euglycemic for 2-3 days, the prognosis is better. Long-term follow-up should include: 1) Recheck blood glucose every 1-3 months for the first year, then every 3-6 months thereafter. 2) Monitor for recurrence of clinical signs (weakness, seizures). 3) Abdominal ultrasound every 3-6 months to assess for metastasis or recurrence. 4) If medical therapy is used, adjust drug dosages based on blood glucose levels and clinical signs. 5) For dogs on diazoxide, monitor for side effects such as vomiting, anorexia, and bone marrow suppression. 6) For dogs on prednisone, monitor for signs of hyperadrenocorticism. 7) Provide dietary counseling to maintain a consistent feeding schedule. 8) Educate owners on how to recognize and manage hypoglycemic episodes at home, including administration of honey or glucose gel. 9) Consider referral to a veterinary oncologist for advanced treatment options if metastasis is detected.

Pearls: 1) Always measure blood glucose after a 12-hour fast, but if clinical signs occur sooner, measure immediately. 2) A single normal blood glucose does not rule out insulinoma; repeated measurements may be needed. 3) The amended insulin-to-glucose ratio (AIGR) is more sensitive than the simple insulin-to-glucose ratio. 4) Abdominal ultrasound is useful for staging but may miss small tumors; CT is more sensitive. 5) Surgical resection is the treatment of choice, but even with successful surgery, recurrence is common. 6) Medical management with diazoxide and prednisone can effectively control clinical signs for months. 7) Always rule out other causes of hypoglycemia, especially sepsis and hepatic disease. Pitfalls: 1) Do not administer glucose orally to a seizing dog; use IV dextrose. 2) Avoid over-supplementation of glucose, as it can stimulate further insulin release. 3) Do not delay surgery if metastasis is suspected; debulking can improve survival. 4) Be cautious with the use of streptozotocin due to its nephrotoxicity; monitor renal function closely. 5) Do not use corticosteroids alone if the dog is diabetic; they can worsen hyperglycemia. 6) Do not forget to check for concurrent diseases such as hypothyroidism or hyperadrenocorticism, which can complicate management.

Drug protocols for insulinoma are based on Plumb's Veterinary Drug Handbook and current literature. 1) Diazoxide: Dogs: 10-40 mg/kg/day PO divided q8-12h. Start at 10 mg/kg/day and titrate upward by 5 mg/kg/day every 3-5 days until clinical signs are controlled. Maximum dose is 40 mg/kg/day. Cats: 5-10 mg/kg/day PO divided q12h. Side effects include vomiting, anorexia, and thrombocytopenia. 2) Prednisone: Dogs: 0.25-0.5 mg/kg PO q12h initially, then taper to the lowest effective dose. Cats: 1-2 mg/kg PO q12h. Use with caution in diabetic patients. 3) Octreotide: Dogs: 10-20 µg/kg SC q8-12h. Cats: 10-20 µg/kg SC q8-12h. Efficacy is variable; may be tried if diazoxide is ineffective. 4) Streptozotocin: Dogs: 500 mg/m² IV every 3 weeks. Administer with saline diuresis to reduce nephrotoxicity. Monitor renal function (BUN, creatinine, urine specific gravity) before each dose. Cats: Not recommended due to severe nephrotoxicity. 5) Dextrose (for emergency): 0.5-1 g/kg IV as a 50% solution diluted 1:1 with saline, given slowly over 5-10 minutes, followed by a constant rate infusion of 2.5-5% dextrose in saline at maintenance rates. 6) Glucagon (for refractory hypoglycemia): 50 ng/kg IV bolus, then 5-10 ng/kg/min CRI. 7) Supportive care: Antiemetics (e.g., maropitant 1 mg/kg SC q24h) if vomiting occurs. 8) For pancreatitis post-surgery: Fluid therapy, analgesia (e.g., fentanyl CRI 2-5 µg/kg/h), and nutritional support. Always adjust dosages based on renal and hepatic function, and monitor for drug interactions.

Key studies and consensus guidelines: 1) A retrospective study by Tobin et al. (1999) evaluated 60 dogs with insulinoma and found that surgical resection improved survival compared to medical management alone, with median survival of 18 months for dogs without metastasis. 2) A study by Polton et al. (2007) reported that dogs with insulinoma and no metastasis had a median survival of 18 months, while those with metastasis had a median survival of 6 months. 3) The use of diazoxide was evaluated in a study by Feldman et al. (1985), showing that it controlled clinical signs in 70% of dogs. 4) A study by Moore et al. (2002) evaluated the use of streptozotocin in dogs with metastatic insulinoma and reported a response rate of 50%, but with significant nephrotoxicity. 5) The ACVIM consensus statement on hypoglycemia (2013) provides guidelines for diagnosis and management of insulinoma. 6) A recent study by Buishand et al. (2018) investigated the role of Ki-67 as a prognostic marker, finding that a Ki-67 index >2.5% was associated with shorter survival. 7) A study by Goutal et al. (2012) compared ultrasound and CT for detection of insulinoma, finding CT to be more sensitive. 8) There are no large randomized controlled trials in veterinary medicine, but the cumulative evidence supports surgical resection as the first-line treatment, with medical management as an alternative for non-surgical candidates.